Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Concerning neuromodulation as treatment of neurological and neuropsychiatric disorder: Insights gained from selective targeting of the subthalamic nucleus, para-subthalamic nucleus and zona incerta in rodents
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Physiology and Environmental Toxicology. Aligning Sci Parkinsons ASAP Collaborat Res Networ, Chevy Chase, MD 20815 USA..
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Physiology and Environmental Toxicology. Aligning Sci Parkinsons ASAP Collaborat Res Networ, Chevy Chase, MD 20815 USA..
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Physiology and Environmental Toxicology. Aligning Sci Parkinsons ASAP Collaborat Res Networ, Chevy Chase, MD 20815 USA..
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Physiology and Environmental Toxicology. Aligning Sci Parkinsons ASAP Collaborat Res Networ, Chevy Chase, MD 20815 USA..ORCID iD: 0000-0002-8713-070x
2024 (English)In: Neuropharmacology, ISSN 0028-3908, E-ISSN 1873-7064, Vol. 256, article id 110003Article in journal (Refereed) Published
Abstract [en]

Neuromodulation such as deep brain stimulation (DBS) is advancing as a clinical intervention in several neurological and neuropsychiatric disorders, including Parkinson 's disease, dystonia, tremor, and obsessivecompulsive disorder (OCD) for which DBS is already applied to alleviate severely afflicted individuals of symptoms. Tourette syndrome and drug addiction are two additional disorders for which DBS is in trial or proposed as treatment. However, some major remaining obstacles prevent this intervention from reaching its full therapeutic potential. Side -effects have been reported, and not all DBS-treated individuals are relieved of their symptoms. One major target area for DBS electrodes is the subthalamic nucleus (STN) which plays important roles in motor, affective and associative functions, with impact on for example movement, motivation, impulsivity, compulsivity, as well as both reward and aversion. The multifunctionality of the STN is complex. Decoding the anatomical -functional organization of the STN could enhance strategic targeting in human patients. The STN is located in close proximity to zona incerta (ZI) and the para -subthalamic nucleus (pSTN). Together, the STN, pSTN and ZI form a highly heterogeneous and clinically important brain area. Rodent -based experimental studies, including opto- and chemogenetics as well as viral -genetic tract tracings, provide unique insight into complex neuronal circuitries and their impact on behavior with high spatial and temporal precision. This research field has advanced tremendously over the past few years. Here, we provide an inclusive review of current literature in the pre -clinical research fields centered around STN, pSTN and ZI in laboratory mice and rats; the three highly heterogeneous and enigmatic structures brought together in the context of relevance for treatment strategies. Specific emphasis is placed on methods of manipulation and behavioral impact.

Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 256, article id 110003
Keywords [en]
Subthalamic nucleus, Para-subthalamic nucleus, Zona incerta, Basal ganglia, Parkinson's disease, Obsessive compulsive disorder, Deep brain stimulation, Transgenics, Genetics, Cre recombinase, Optogenetics, Chemogenetics, Neurocircuitry, Subpopulation, Heterogeneity
National Category
Neurology Neurosciences
Identifiers
URN: urn:nbn:se:uu:diva-534971DOI: 10.1016/j.neuropharm.2024.110003ISI: 001258314800001PubMedID: 38789078OAI: oai:DiVA.org:uu-534971DiVA, id: diva2:1884004
Funder
Swedish Research CouncilParkinsonfondenAvailable from: 2024-07-12 Created: 2024-07-12 Last updated: 2024-07-12Bibliographically approved

Open Access in DiVA

fulltext(15165 kB)584 downloads
File information
File name FULLTEXT01.pdfFile size 15165 kBChecksum SHA-512
c81100aa76885d5200bc3d4ee3ff6ecbe895d6b158cce02d2ff47537910afc754a092f537696e9515531e4a2579d6a645a5cb47c612bbd840c461a22098855a7
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ricci, AlessiaRubino, EleonoraSerra, Gian PietroWallén-Mackenzie, Åsa
By organisation
Physiology and Environmental Toxicology
In the same journal
Neuropharmacology
NeurologyNeurosciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 585 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 720 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf